The therapeutic community is abuzz with anticipation surrounding retatrutide, a innovative dual GIP and GLP-1 target that’s showing significant efficacy in clinical trials for treating obesity. Unlike some available weight loss treatments, retatrutide appears to offer a significant substantial de